This website uses cookies and similar technologies to deliver its services, to analyse and improve performance and to provide personalised content and advertising. Information about your use of this website will be shared with Google and other third parties. Read our privacy policy.
2015-11-03T00:00:00Z
Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate
